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Hypothesis: Lung cancer remains the leading cause of cancer-
related mortality worldwide. Currently known serum markers do not
efficiently diagnose lung cancer at early stage.
Methods: In the present study, we developed a serum proteomic
fingerprinting approach coupled with a three-step classification
method to address two important clinical questions: (i) to deter-
mine whether or not proteomic profiling differs between lung
cancer and benign lung diseases in a population of smokers and
(ii) to assess the prognostic impact of this profiling in lung
cancer. Proteomic spectra were obtained from 170 pathologically
confirmed lung cancer or smoking patients with benign chronic
lung disease serum samples.
Results: Among the 228 protein peaks differentially expressed in
the whole population, 88 differed significantly between lung cancer
patients and benign lung disease, with area under the curve diag-
nostic values ranging from 0.63 to 0.84. Multiprotein classifiers
based on differentially expressed peaks allowed the classification of
lung cancer and benign disease with an area under the curve ranging
from 0.991 to 0.994. Using a cross-validation methodology, diag-
nostic accuracy was 93.1% (sensitivity 94.3%, specificity 85.9%),
and more than 90% of the stage I/II lung cancers were correctly
classified. Finally, in the prognosis part of the study, a 4628 Da
protein was found to be significantly and independently associated
with prognosis in advanced stage non-small cell lung cancer patients
(p  0.0005).
Conclusions: The potential markers that we identified through
proteomic fingerprinting could accurately classify lung cancers in a
high-risk population and predict survival in a non-small cell lung
cancer population.
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Lung cancer is a worldwide clinical problem and a majorcause of cancer deaths. More than 150,000 new cases are
diagnosed in Europe every year and overall mortality is
increasing, with an overall 5-year survival rate of 6 to 16%.1
This poor prognosis is primarily related to propensity for
early spread and late diagnosis of lung cancer. Approximately
87% of lung cancers are smoking related due to active or
second hand tobacco smoking.2 The identification of early
stages of lung cancer and an efficient screening of this
high-risk population of smoking patients would enable earlier
treatment, which seems to clearly improve outcome, with a
5-year survival rate reaching up to 60 to 70% for stage I
surgically-treated patients3,4 and up to 88% in a screening
population.5 However, despite many intensive studies, no
efficient screening or early diagnosis methods have been
validated so far. The old screening trials using chest radiog-
raphy or sputum cytologic analysis have thus far been unable
to decrease lung cancer mortality in the high-risk population
of smoking individuals.2,6 The survival impact of low-dose
spiral computerized tomography (CT) screening is currently
evaluated by randomized clinical trials.5,7,8 This limitation
has spurred continued interest in identifying reliable tumor
markers that can be detected in serum. Tumor markers, such
as Carcinoembryonic Antigen, Neuron Specific Enolase
(NSE) and Cyfra 21-1 are mostly used as complementary
tools to establish the initial diagnosis,9 to assess the efficacy
of treatment and to monitor evidence of relapse. Their low
diagnostic value prevent their use in the screening setting. A
noninvasive technique based on reliable diagnosis markers
will be useful in this setting.
Recent advances in proteomic instrumentation, such as
surface-enhanced laser desorption ionization/time-of-flight
mass spectrometry (SELDI/TOF-MS) technology, and com-
putational methodologies offer a unique chance to rapidly
identify these new candidate markers.10 Using SELDI/TOF-
MS, we aimed to address two important clinical questions:
first, the determination of a serum proteomic fingerprints
from lung cancer patients and control subjects, which have a
high-risk of developing this cancer in order (i) to determine
whether or not proteomic profiling differs between lung
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cancer and benign lung diseases in a population of smokers
and (ii) to assess the prognostic impact of this profiling in
lung cancer. In the first part of the study (discriminating value
analysis), we analyzed spectra using a three-step algorithm
and then assessed whether our pattern of markers could be
used to discriminate lung cancer and benign lung disease. In
the prognostic part of the study, we analyzed spectra of a
homogeneous subpopulation of advanced non-small cell lung
cancer (NSCLC) patients in search of new prognostic tumor
markers.
PATIENTS AND METHODS
Study Population
Sera from pathologically confirmed lung cancer and
benign tobacco-induced or tobacco-associated chronic lung
disease patients were collected at the Thoracic Oncology Unit
of the University Hospital (Montpellier, France) with institu-
tional approval. Diagnosis of lung cancer was based on
histologic analysis of fiberoptic lung biopsies or surgical
resections and cancers were classified as small cell lung
cancers and NSCLC (including squamous cell carcinomas,
adenocarcinomas, and large cell carcinomas). The benign
disease patients were collected during the same accrual pe-
riod. Patients in the benign chronic lung disease group were
affected by diseases resulting of (chronic obstructive pulmo-
nary disease with or without infectious complications, n 
17) or worsened by (postinfectious bronchectasis, silicosis,
severe asthma, n 6) tobacco consumption, without previous
or concomitant diagnosis of malignant disease. Whole blood
was collected during fasting. Serum was separated by cen-
trifugation for 20 minutes at 4000 rpm, aliquoted, and frozen
at 80°C.
Proteomic Analysis
To optimize the peak resolution and the number of
protein peaks detected, an anion-exchange fractionation pro-
cedure was performed as described previously.11 Briefly, 20
l of serum samples were denaturated in 9 M Urea, 2%
3-[(2-cholamidopropyl)-dimethylammonio]-1-propane-sulfo-
nate hydrate (CHAPS), and 50 mM Tris-HCl, pH 9, and then
separated on a 96-wells filter plate containing Qhyperd F
resin (BioSepra Corp., Fremont, CA) into 6 different pH
gradient elution fractions, referred as to F1 (pH 9), F2 (pH 7),
F3 (pH 5), F4 (pH 4), F5 (pH 3), and F6 (organic elution).
Each fraction was randomly applied to a CM10 array surface.
F2 was not subjected to analysis due to the weak number of
peaks detected in preliminary experiments. Sinapinic acid
solution was applied as an energy absorbing matrix twice to
each spot. Arrays were read on a phosphate-buffered saline II
ProteinChip reader. Reproducibility was estimated using a
human control serum (Ciphergen Biosystems), which was
randomly spotted onto each chip to measure the variability of
fractionation, on-chip spotting, and data acquisition. Spectra
were background subtracted and the peak intensities were
normalized in each fraction to the total ion current of m/z
between 2.5 and 50 kDa. Peak detection was performed using
the ProteinChip and Biomarker Wizard software (Ciphergen
Biosystem). Automatic peak detection was performed in the
range of 2.5 to 50 kDa with the following settings: (i)
signal-to-noise ratio at four for the first pass and two for the
second pass, (ii) minimal peak threshold at 15% of all spectra,
(iii) cluster mass window at 0.5% of mass. The resulting file
containing absolute intensity and m/z ratio values was ex-
ported into Microsoft Excel for subsequent analysis.
Statistical Data Analysis
The most discriminating markers between lung cancer
and benign diseases were selected in three steps: (1) As peaks
were defined by their intensities, the assumption of equality
of intensities in the two groups was tested by a two-sided
Wilcoxon test. Bonferroni‘s correction was not used due to
the large number of tested peaks. Hence, a significant p value
of 0.01 was chosen from the histogram of the 228 p values
and corresponded to a break point in the histogram; (2) Both
forward and stepwise procedures of logistic regression were
used for final peak selection; (3) The selected markers abil-
ities to differentiate were tested using a cross-validation class
prediction analysis. Briefly, a random selection of training
and test samples was built with 80% and 20% of the total
population, respectively. A class prediction model was de-
fined from the training samples using different supervised
classification methods and was then used to predict the class
of the test samples. Moreover, the model selection robustness
was confirmed by using different training sample sizes that
varied from 40, 60, and 80% of the total sample size (n 
170). The process was repeated 1000 times to improve the
consistency, robustness, and validity of the model.
For survival data analysis, the significant proteins were
selected with the same method. Survival was calculated from
the date of histologic diagnosis to the time of death, with at
least 1 year follow-up duration. In this study, a poor progno-
sis group was defined as a population with an overall survival
shorter than 12 months. This time to event is the current
median survival for patient with advanced NSCLC treated
with conventional first line chemotherapy. Patients alive at
the time of follow-up were censored at this date. Kaplan–
Meier survival curves were compared by the log-rank test
with a cutoff value of p  0.0001. We estimated the perfor-
mance value of our classifier together with classic clinical and
biologic features using the threshold defined in previous
publications.3,12–15 The cutoff point was p  0.05 for univar-
iate analysis (log-rank test). Variables with a univariate p
value0.1 were considered to be entered into a stratified Cox
proportional hazard model. The cutoff point was p 0.05 for
the Cox model results.
Immunoassay Quantification
The two tumor markers, Cyfra21-1 and NSE, were
measured in the 170 sera using a Kryptor immunoassay
system (Brahms) with cutoff values of 3.6 and 12.5 ng/ml,
respectively.
RESULTS
Patients’ Characteristics
The clinicopathologic characteristic of patients and
samples are given in Table 1. These included 147 lung cancer
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and 23 benign disease samples. Of the 147 lung cancer
samples assayed, most patients had advanced lung cancer
(87%) and 13% had early lung cancer diseases.
Lung Cancer Versus Benign Disease Serum
Proteomic Fingerprinting
To increase the success rate of marker discovery, we
first fractionated the serum samples based on the pIs of the
proteins into 6 fractions. We then profiled each fraction on
CM10 arrays by SELDI/TOF-MS. To evaluate the variability
of SELDI, we first tested the experimental reproducibility
using a human serum control. The coefficients of variation of
15 reliable peaks were calculated by averaging peak intensity
values derived from 40 different runs. The average coefficient
of variations were 10% and 17%, respectively, for intra- and
inter-assay variability, which is consistent with previously
reported studies.16–19 A total set of 228 protein peak clusters
ranging from 2 to 80 kDa were obtained from the 170 serum
samples. According to our first statistical criterion, we se-
lected 88 of the 228 protein peaks that were significantly
differentially expressed between lung cancer and benign lung
disease population samples (p  0.01). Among these peaks,
67 were overexpressed and 21 were underexpressed in lung
cancer compared with benign samples. The diagnostic values
area under the curve (AUC) of each of these 88 differentially
expressed peaks ranged from 0.63 to 0.84 (Table 2). A
representative example of three discriminating protein peaks
is shown in Figure 1.
To identify a multiprotein signature that can distinguish
the lung cancer and benign populations, we used a three-step
statistical process. After peak selection, forward and stepwise
logistic regression were used to construct two multiprotein
classifiers composed of seven and eight protein peaks, respec-
tively. Interestingly, six protein peaks were common to the
two models, confirming the robustness of the model selection.
Both composite indices yielded higher AUC values (0.991
and 0.994) than the individual protein peaks (ranging from
0.67–0.833). In the same way, the AUC values from our
multiprotein index were higher than those of the two classic
lung cancer markers, NSE and Cyfra 21-1, or their combina-
tory index (Figure 2). We next applied our classifiers to
cross-validation test samples to estimate their accuracy. Table
3 indicates the mean performance of our classifiers on 1000
randomly generated 80:20 sets of samples by use of different
class-prediction models. Linear discriminant analysis (LDA)
associated with the forward multiprotein classifier gave the
best performance result for discriminating lung cancer and
benign samples, achieving an overall classification accuracy
of 93.1. Considering the estimated prevalence of lung cancer
in high-risk populations of 3.2%, we evaluated the positive
predictive value and the negative predictive value in our
high-risk population to 18.1 and 99.8, respectively. Interest-
ingly, the mean performance of the LDA forward multipro-
tein classifier remained unchanged with a mean specificity
ranging from 85.6 to 86.2%, and sensitivity from 93.2 to
94.3% with a training set of 40% instead of 80% (Table 4).
Finally, to estimate the misclassification rate of early stage
lung cancer in our population (stage I–II, n 19), we applied
the different class-prediction models to cross-validation test
TABLE 1. Patient’s Characteristics
Variables Patients
Chronic lung diseases 23
Age
Median (range) 70 (53–84)
Sex
Male 17 (74%)
Female 6 (26%)
Smoking history
Never 0
Former 14 (61%)
Active 9 (39%)
Lifetime pack-years
Median (range) 40 (2–100)
Diagnosis
COPD 14 (61%)
COPD  infectious complications 3 (13%)
Severe asthma 3 (13%)
Bronchectasis 2 (9%)
Silicosis 1 (4%)
Lung cancer 147
Age
Median (range) 62 (32–83)
Sex
Male 115 (78%)
Female 32 (22%)
Smoking history
Never 14 (10%)
Former 58 (39%)
Active 75 (51%)
Lifetime pack-years
Median (range) 39 (0–150)
Histology
Small cell carcinoma 20 (14%)
Squamous cell carcinoma 40 (27%)
Adenocarcinoma 55 (37%)
Large cell carcinoma 32 (22%)
Tumor status
1–2 45 (31%)
3–4 102 (69%)
Nodal status
0–1 57 (39%)
2–3 90 (61%)
Metastatic status
0 63 (43%)
1 84 (57%)
Stage grouping (Mountain)
I a 2 (1%)
I b 3 (2%)
II a 3 (2%)
II b 11 (7%)
III a 17 (12%)
III b 27 (18%)
IV 84 (57%)
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TABLE 2. Differentially Expressed Markers
m/z Fraction p AUC
Peak Intensity
Fold ChangeChronic Lung Disease Lung Cancer
5916.65 F1 0.00000008 0.822 11.901 32.027 2.7
6122.65 F1 0.0000001 0.812 2.092 8.086 3.9
3203.06 F1 0.0000001 0.822 3.293 9.960 3.0
3274.03 F1 0.0000001 0.842 4.523 13.923 3.1
26562.70 F3 0.0000003 0.822 0.105 0.191 1.8
7172.00 F6 0.0000004 0.812 29.932 12.748 0.4
6099.92 F1 0.0000008 0.792 2.557 7.680 3.0
77993.59 F5 0.000004 0.802 0.304 0.424 1.4
39845.94 F3 0.000005 0.782 0.541 0.894 1.7
14787.64 F6 0.000005 0.761 4.235 6.466 1.5
66755.68 F5 0.000007 0.782 7.264 10.822 1.5
4823.63 F1 0.000007 0.792 12.964 8.032 0.6
60854.55 F5 0.00001 0.761 0.148 0.237 1.6
56265.52 F6 0.00002 0.761 3.870 7.044 1.8
33419.79 F5 0.00002 0.782 4.709 6.401 1.4
9293.28 F1 0.00002 0.761 7.848 14.516 1.8
51405.19 F5 0.00002 0.751 0.441 0.582 1.3
12880.15 F6 0.00002 0.751 17.104 26.425 1.5
53762.91 F3 0.00002 0.751 0.052 0.079 1.5
42221.83 F6 0.00002 0.761 0.595 1.004 1.7
14159.08 F6 0.00002 0.751 19.752 28.870 1.5
45459.28 F6 0.00003 0.751 1.499 2.371 1.6
44606.65 F5 0.00005 0.681 0.426 0.586 1.4
14059.26 F6 0.00005 0.751 19.752 28.870 1.5
41148.13 F6 0.00006 0.761 0.424 0.742 1.8
7474.29 F1 0.00007 0.741 4.979 9.011 1.8
79502.96 F3 0.0001 0.731 0.929 1.422 1.5
6443.14 F6 0.0001 0.721 85.467 58.230 0.7
17270.63 F6 0.0001 0.741 15.773 23.151 1.5
58792.16 F4 0.0002 0.721 0.150 0.204 1.4
28292.37 F6 0.0002 0.721 31.761 43.976 1.4
6643.25 F6 0.0002 0.721 97.164 62.184 0.6
9725.59 F6 0.0002 0.721 43.027 32.935 0.8
9436.27 F5 0.0002 0.711 24.897 14.428 0.6
40295.53 F4 0.0002 0.721 0.191 0.284 1.5
48867.54 F3 0.0003 0.731 0.137 0.175 1.3
9294.82 F5 0.0003 0.741 4.901 6.479 1.3
14502.12 F5 0.0003 0.701 6.667 8.838 1.3
9728.00 F5 0.0003 0.711 8.772 5.791 0.7
28108.87 F6 0.0004 0.701 41.366 55.348 1.3
7657.77 F1 0.0004 0.741 3.171 4.845 1.5
34682.28 F5 0.0004 0.721 3.286 4.467 1.4
9436.99 F6 0.0005 0.691 58.600 51.184 0.9
12622.71 F6 0.0007 0.721 7.202 11.239 1.6
3325.15 F6 0.0007 0.691 26.495 14.322 0.5
17258.20 F5 0.0007 0.731 1.871 2.894 1.5
28948.57 F6 0.0007 0.691 14.994 19.807 1.3
13088.56 F6 0.0007 0.731 5.331 7.438 1.4
9653.85 F6 0.0008 0.721 43.027 32.935 0.8
8825.22 F6 0.0008 0.691 74.777 55.742 0.7
8930.98 F6 0.0009 0.711 62.084 48.242 0.8
4414.32 F6 0.0010 0.691 22.192 14.098 0.6
10275.04 F1 0.001 0.711 4.264 8.368 2.0
(Continued)
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samples. Using our classifiers, 89.5 to 100% of the early stage
lung cancer samples were correctly classified (data not shown).
NSCLC Prognosis
We next searched for a correlation between a multipro-
tein signature and the clinical outcome of patients. We first
selected a homogeneous population of 87 stage III–IV NSCLC
patients receiving conventional first line chemotherapy with
exhaustive clinical and biologic pretherapeutic prognostic
data and at least a 1 year follow-up duration. Using our
three-step statistical test, we constructed a predictive survival
classifier composed of only one protein peak at 4628 Da
(fraction 5), which can predict by itself the clinical outcome
of patients (Figure 3). The robustness and performance of the
predictive value of this potential marker were verified with
our cross-validation (Table 3). The protein peak at 4628 Da
divided patients into a group with poor prognosis (overall
survival shorter than 12 months, n  33) and one with good
prognosis (overall survival longer than 12 months, n  54)
with a highly significant difference (p  0.0001 according to
the Log-rank test, Figure 4) and a peak intensity threshold of
32.25. Finally, we estimated the performance value of this
new prognostic factor together with classic clinical and bio-
logic features in this population (Table 5). In multivariate
analysis, four variables were independent determinants of a
poor outcome: stage grouping, age, performance status, and
the 4628 Da marker (Table 6). Interestingly, the 4628 Da
marker showed the strongest statistically significant associa-
tion with clinical outcome (Hazard Ratio  3.45 [95%
confidence interval 1.22–6.14], p  0.0005). It is worth
noting that this marker remained as the only biologic variable
statistically associated with a poor outcome, in contrast to the
classic NSCLC tumor markers.
TABLE 2. (Continued)
m/z Fraction p AUC
Peak Intensity
Fold ChangeChronic Lung Disease Lung Cancer
17399.18 F5 0.001 0.711 2.535 3.837 1.5
6678.33 F5 0.001 0.671 23.701 27.568 1.2
25697.08 F5 0.002 0.691 0.343 0.490 1.4
22758.13 F6 0.002 0.691 0.927 1.323 1.4
8149.31 F5 0.002 0.701 0.883 2.195 2.5
17385.43 F5 0.002 0.711 2.535 3.837 1.5
6464.33 F5 0.002 0.701 8.099 11.334 1.4
17596.60 F6 0.002 0.691 9.084 12.029 1.3
9143.29 F6 0.002 0.671 30.374 23.160 0.8
59019.37 F5 0.002 0.701 0.186 0.246 1.3
17157.64 F6 0.002 0.681 5.366 9.056 1.7
22270.43 F3 0.002 0.681 0.645 0.798 1.2
26214.75 F6 0.002 0.681 0.865 1.291 1.5
6631.31 F5 0.003 0.701 58.236 45.857 0.8
36938.75 F6 0.003 0.681 1.003 1.381 1.4
6432.63 F5 0.003 0.681 30.440 22.909 0.8
44678.99 F4 0.003 0.711 0.423 0.492 1.2
13891.22 F6 0.003 0.681 4.850 7.090 1.5
7770.31 F4 0.003 0.701 6.800 3.457 0.5
4720.56 F6 0.003 0.661 26.113 19.651 0.8
14163.93 F4 0.005 0.660 6.626 8.803 1.3
28123.05 F4 0.005 0.671 3.853 5.686 1.5
52072.00 F6 0.005 0.661 0.426 0.492 1.2
6850.63 F6 0.006 0.681 33.476 24.106 0.7
34754.05 F6 0.006 0.681 1.815 2.355 1.3
23227.41 F5 0.007 0.681 0.735 0.840 1.1
21098.20 F4 0.008 0.661 0.286 0.364 1.3
4476.78 F6 0.008 0.661 20.076 14.882 0.7
8931.48 F5 0.008 0.651 10.044 7.227 0.7
13883.37 F4 0.008 0.651 10.375 13.960 1.3
6946.05 F4 0.009 0.661 9.121 11.858 1.3
3327.54 F1 0.009 0.631 6.180 9.397 1.5
28318.09 F4 0.009 0.661 2.581 3.657 1.4
60794.67 F3 0.009 0.651 0.275 0.393 1.4
21784.52 F6 0.009 0.651 1.133 1.474 1.3
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DISCUSSION
A possible development to improve the early diagnosis
of the lung cancer could be to simultaneously screen for
multiple markers. Using SELDI-TOF, we sought to prospec-
tively classify lung cancer patients and smoking individuals
with benign lung disease on the basis of the mass protein
spectra of their sera and found that simple profiles can
statistically significantly predict in our population the cancer
status of patients and their survival.
Proteomic fingerprinting by SELDI-TOF has been suc-
cessfully applied in identifying early detection markers in
multiple cancers.16,19–25 However, few reports have shown
that serum proteomic fingerprints by SELDI-TOF or other
proteomic approaches, can distinguish lung cancer patients
from control subjects.26–37 Indeed, these studies have been
limited by the use of only some histologic forms of lung
cancer and the use of healthy subjects as a control population,
which may induce selection bias. In contrast, and for the first
time to our knowledge, our study was based on an unselected
population of lung cancer patients, including patients suffer-
ing from large cell carcinoma, a population excluded in
previously studies. Moreover, since active or second hand
tobacco smoking is responsible for approximately 87% of all
lung cancer, we selected our control population to include
patients at risk for lung cancer, such as patients suffering
from tobacco-induced or tobacco-worsened chronic lung dis-
eases. One major advantage of both the pathologic and
control populations used here is that they allowed for analysis
of the most realistic situation for a screening setting that
could be proposed in clinical practice.
FIGURE 1. Representative SELDI-TOF spectra obtained
from chronic lung disease and lung cancer serum sam-
ples. (A) Overlay of protein mass spectra. Protein mass
spectra obtained from sera of patients with lung cancer
(red) and noncancer individuals (blue) are superimposed.
Differential variations in intensity indicate potential markers.
(B) Representative spectra from 3 patients with chronic lung
disease (upper panel) and 3 patients with lung cancer (lower
panel); the depicted peaks were identified by statistical anal-
ysis as optimally discriminatory. Frames indicate the posi-
tions of 3 peaks at 5916, 6100 and 6122 Da, respectively,
overexpressed in fraction 1 of lung cancer patients (right
panel) and one peak at 7172 Da underexpressed in fraction
6 of lung cancer patients.
FIGURE 2. ROC curves for the lung cancer multiprotein
index and both classic lung cancer markers (NSE and Cyfra
21-1). ROC curves for the forward (A) and the stepwise (B)
multiprotein indices, as well as for the composite index of
NSE and Cyfra 21-1, are plotted. The areas under the ROC
curves are 0.991 (A), 0.994 (B) and 0.828 (C) and are com-
pared with the individual markers.
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The most important steps in proteomic studies are the
differential and statistical analysis of all the data from spec-
tra. To analyze our data, we searched for a combination of
methods that could reliably detect lung cancer in a high-risk
population. We developed a three-step strategy to extract
combinations of markers and to evaluate the robustness of
these classifiers. Our multivariate analysis first identified
combinations of seven and eight protein peaks with AUCs of
0.991 and 0.994, respectively. Then, since there is no “gold-
standard” method for classification of mass spectrometry
data, we were interested in testing the validity and robustness
of these multiprotein classifiers by using different classifica-
tion methods. We compared the performance of these various
supervised classification methods by the standard leave-and-
out cross-validation method. Interestingly, we observed that
once the most discriminating markers were selected, the
results for sensitivity, specificity, and accuracy can be radi-
cally different from one classification method to another.
From our data, LDA, associated with the forward multipro-
tein classifier, gave the best performance result to discrimi-
nate lung cancer and benign samples, achieving an overall
classification accuracy of 93.1, a sensitivity of 94.3, and a
specificity of 85.9. Using the most common decision tree
classification method, previous studies comparing healthy
subjects and lung cancer patients showed similar sensitivities
and specificities to those reported here.32,33 However, using
our data, methods based on decision tree classification meth-
ods failed to correctly classify individuals from our control
group with specificities lower than 38%. These results can
probably be largely explained by the fact that we have chosen
high-risk individuals as a control group, whereas the classi-
fication methods based on a decision tree used thresholds. It
would be interesting to ensure a medium term follow-up of
this control population to rule out the possibility of infra-
clinical and radiologic cancer development, which should
allow the reallocation of some of these individuals into the
correct group. Finally, and importantly, the choice of a
classification method will depend on the data, the preselec-
tion method used and the problem that has to be solved.
Therefore, we believe that the LDA remained the most robust
method, allowing for accurate detection of lung cancer in a
high-risk population.
One of the principal aims of research in lung cancer is
to find efficient screening or early diagnosis methods, which
would enable earlier treatment by curative tumor resection
and improve the outcome of patients. Recently, screening
trials using low-dose spiral CT have encouraged a resurgence
of interest in the prevention of lung cancer.5,7,8,38 However, a
recent review reported a positive CT examination rate from
5.1 to 51%, whereas lung cancer prevalence in the high-risk
population screened was 3.2%.39 The high resolution of the
low-dose spiral CT thus seems to detect very small lesions,
leading to overdiagnosis and thus invasive procedures for
benign lesions. In this context, and to reduce the unnecessary
TABLE 3. Diagnostic and Prognostic Performance of Classifiers
Tested
Population
High Risk
Population*
Model Accuracy Sensitivity Specificity PPV NPV PPV NPV
Diagnostic index
Forward multiprotein index
Support vector machine 92.8 95.1 79.8 96.5 73.6 13.5 99.8
Linear discriminant analysis 93.1 94.3 85.9 97.5 72.4 18.1 99.8
Quadratic discriminant analysis 91.7 94.1 78.0 96.1 69.4 12.4 99.7
Neural networks 94.2 97.7 74.0 95.6 84.8 11.0 99.9
Classification tree 82.3 91.6 28.6 88.1 36.9 4.1 99.0
Boosting tree 81.4 98.1 16.8 82.0 70.0 3.8 99.6
Stepwise multiprotein index
Support vector machine 93.5 96.4 76.3 95.9 78.6 11.8 99.8
Linear discriminant analysis 93.6 95.3 83.7 97.1 75.4 16.2 99.8
Quadratic discriminant analysis 90.9 94.6 69.8 94.8 69.0 9.4 99.7
Neural networks 95.7 98.8 77.8 96.3 91.9 12.8 99.9
Classification tree 82.3 91.6 28.3 88.1 36.8 4.1 99.0
Boosting tree 86.5 95.9 38.1 88.9 64.5 4.9 99.6
Prognostic index
Support vector machine 73.4 71.0 76.6 79.1 67.7 — —
Linear discriminant analysis 74.8 82.0 65.2 74.7 74.8 — —
Quadratic discriminant analysis 69.6 86.0 49.3 67.9 73.7 — —
Neural networks 72.7 73.0 72.7 76.9 68.0 — —
Classification tree 68.8 68.0 70.1 73.9 63.5 — —
Boosting tree 72.5 75.0 69.0 75.2 69.1 — —
*Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were estimated for the tested population and for a high-risk
population (with a prevalence of 3.4%).
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use of such procedures, a screen based upon our results could
be employed before a spiral CT scan as a two-step screening
policy. Considering the sensitivity and specificity of our
proteomic profiles and the expected prevalence of lung cancer
in the high-risk population, one can expect an extrapolated
PPV of 18.11% and a NPV of 99.78%. The herein reported
study included a low proportion of patients suffering from
early stage NSCLC precluding any firm conclusion regarding
the putative ability to differentiate this population subset from
patients suffering from nonmalignant pulmonary diseases and
other malignancies. The further step of our research program
will take into account this important methodological point by
focusing on early stage NSCLC. Because of the high NPV,
the negative test population could be spared of invasive or
irradiating procedures. Patients with suspected lung cancer
should be offered a thoracic CT scan to further progress into
the diagnostic procedure.
A considerable amount of both clinical and preclinical
research has focused on the role of prognostic factors in the
multidisciplinary care of patients affected by NSCLC. Up to
now, the most widely-accepted prognostic determinants of
NSCLC are disease stage and performance status.3,40 The
prognostic impact of classic tumor markers has been evalu-
ated, but their use needs to be improved.13–15 In the present
study, the prognostic utility of the tumor marker identified
seems to be superior to the one produced by classic tumor
markers. In the Cox model, the 4628 Da protein peak was
found to be the only statistically significant independent
biologic prognostic variable. Interestingly, classic clinical
FIGURE 3. Representative view of the predictor of clinical
outcome. (A) Overlay of protein mass spectra. Protein mass
spectra obtained from sera of patients with good prognoses
(red) and poor prognoses (blue) are superimposed. (B) Rep-
resentative spectra from 3 patients with good prognoses
(upper panel) and 3 patients with poor prognoses (lower
panel). Frames indicate the position of the 4628 Da prog-
nostic protein peak.
TABLE 4. Robustness of Cross-Validation
Model
Training
Sample
Size (%) Accuracy Sensitivity Specificity
Forward multiprotein
index
Support vector
machine
80 92.8 95.1 79.8
60 92.2 94.6 77.5
40 91.4 94.6 71.2
Linear discriminant
analysis
80 93.1 94.3 85.9
60 92.8 93.8 86.2
40 92.3 93.2 85.6
Quadratic discriminant
analysis
80 91.7 94.1 78.0
60 91.6 94.9 71.4
40 91.3 99.2 45.6
Neural networks 80 94.2 97.7 74.0
60 94.2 97.5 73.2
40 92.8 97.5 65.5
Classification tree 80 82.3 91.6 28.6
60 82.7 90.9 30.0
40 82.3 91.2 26.5
Boosting tree 80 81.4 98.1 16.8
60 85.4 98.2 22.4
40 85.6 98.7 22.0
Stepwise multiprotein
index
Support vector
machine
80 93.5 96.4 76.3
60 93.7 96.4 73.8
40 93.4 97.0 66.8
Linear discriminant
analysis
80 93.6 95.3 83.7
60 93.4 94.5 86.0
40 92.3 93.4 84.8
Quadratic discriminant
analysis
80 90.9 94.6 69.8
60 91.0 95.7 60.9
40 91.4 97.4 30.3
Neural networks 80 95.7 98.8 77.8
60 97.2 98.4 86.4
40 95.7 97.9 78.4
Classification tree 80 82.3 91.6 28.3
60 83.2 91.6 29.4
40 82.9 92.1 25.2
Boosting tree 80 86.5 95.9 38.1
60 93.7 96.0 55.9
40 94.3 95.9 58.1
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variables associated with poor prognosis in a NSCLC popu-
lation, namely stage grouping, age, and performance status,
were also retained in the Cox model, arguing for the conven-
tional characteristics of the studied population. A better
definition of prognostic determinants affecting a population
of NSCLC patients may be important in both clinical trials
and routine practice,41–44 either to allow a better stratification
of patients in clinical trials or to consider different treatments
depending on the overall prognosis of a patient. Further
identification and determination whether or not this 4628 Da
protein is a therapeutic or surrogate biomarker will be of
importance. Validation in an independent population, of a
more discriminating tumor marker, such as the 4628 Da
protein peak, could then improve clinical management of this
population. The majority of newly diagnosed NSCLC pa-
tients are affected by advanced stage and survival improve-
ments are slow despite recent introduction of targeted thera-
pies in this setting. Therefore, one can hypothesize that
improving tools able to define outcome will also help in
designing randomized therapeutic studies with accurate strat-
ification variables.
There are some statistical limitations in this study that
need to be addressed. First, the relatively low specificity
obtained with our data could be explained by the strong
imbalance in the size of both sample groups or by the choice
of individuals with a high risk of cancer as control group.
Second, although we did not have enough samples to perform
an independent validation test, we have used a rigorous and
well-accepted cross-validation method to estimate the classi-
fication accuracy of our multiprotein classifiers. Even with a
training set of 40% instead of 80%, as described, all the
selection methods were stable and the LDA remained the
most robust method. However, validation studies are manda-
tory to validate the protein peak combinations’ accuracies in
independent populations. This further validation study will
need a larger cohort of patients suffering from non malignant
pulmonary diseases to ascertain our proteomic profile reli-
ability. Nevertheless, our data strongly illustrate the strength
of serum profiling studies with screening/diagnosis and prog-
nosis objectives.
In conclusion, we found that serum SELDI protein
profiling can distinguish lung cancer patients from patients
affected by benign lung diseases with higher sensitivity and
specificity than any other molecular markers identified to
date. A validation study of the discriminating value of this set
of proteins remains mandatory. Although the incidence of
lung cancer does not yet justify a screening policy for the
general population, the multiprotein index developed in this
study may have clinical importance in a high-risk population.
We also found a specific serum protein that can be used to
identify patients with good or poor prognosis. Altogether,
these results are promising in terms of identification of new
predictive and early diagnosis markers of lung cancer. The
identification and development of specific tests against se-
lected proteins will be needed to enable routine testing of the
performance of these markers in comparison with other
classic tumor markers.
FIGURE 4. Kaplan–Meier survival curves from groups with good and poor prognosis according to the serum protein-based
classification. Circles represent censored patients. p  0.0001 according to Log-rank test.
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